首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2038963

神經病學藥物市場：依疾病、藥物類別、給藥途徑、通路和地區分類。

Neurology Drugs Market, By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月03日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年神經病學領域的醫藥市場規模估計為740億美元，預計2033年將達到1,040億美元。預計2026年至2033年，該市場將以4.98%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	740億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.98%	2033年市場規模預測：	1040億美元

全球神經系統治療市場是製藥業的關鍵領域，涵蓋了影響中樞和周圍神經系統的複雜疾病的治療。

神經系統藥物涵蓋多種疾病的治療，例如癲癇、阿茲海默症、帕金森氏症、多發性硬化症、偏頭痛和中風。神經系統藥物市場的成長主要受神經系統疾病盛行率上升、人口老化、對神經生物學機制的深入了解等因素所驅動。神經系統疾病盛行率的上升，尤其是在已開發國家和新興國家，是推動神經系統藥物市場成長的主要因素。

同時，製藥公司也積極進行研發工作，推動藥物遞送、個人化醫療以及各種疾病新治療方法的引進。神經系統疾病的治療涉及複雜的風險因素，因此市場監管嚴格，且對臨床檢驗的需求也很高。此市場成長要素包括專利到期、學名藥的出現、醫療基礎設施的變革以及臨床指南的更新。此外，基因療法、免疫療法和精準醫療正在改變目前的治療方法，為疾病管理創造了新的機會。

市場動態

全球神經系統藥物市場受多種因素驅動，包括人口結構、技術和醫療保健。人口老化導致失智症、帕金森氏症和癲癇等疾病的盛行率不斷上升，推動了神經系統藥物市場的成長。藥物研發技術的進步，例如人工智慧的應用、生物標記辨識和精準醫療的應用，也進一步促進了市場成長。此外，新興市場醫療保健支出的增加、診斷技術的進步以及醫療基礎設施的不斷完善，也推動了神經系統藥物市場的成長。

然而，這個市場也面臨許多挑戰。具體而言，高昂的研發成本和監管核准是參與企業的障礙。此外，專利到期加劇了學名藥領域的競爭，影響了各公司的獲利能力。臨床試驗的挑戰、倫理問題以及後期藥物研發的高失敗率也是該市場面臨的其他挑戰。此外，安全問題和副作用的發生使得健全的監測系統在該市場中至關重要。

儘管面臨這些挑戰，該市場仍蘊藏著許多機會。這一趨勢在新興市場和開發中國家的醫療基礎設施和醫療旅遊業正在蓬勃發展。用於治療神經系統疾病的孤兒藥、數位療法、聯合治療和藥物傳遞系統代表著該市場未來的成長機會。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數創建了全球神經系統治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球神經系統藥物市場報告旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球神經系統藥物市場中使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

F. Hoffmann-La Roche
Johnson &Johnson
AbbVie
Merck &Co
Teva Pharmaceutical Industries
Eisai
Lundbeck
UCB
Otsuka Pharmaceutical
Jazz Pharmaceuticals

第10章分析師建議

機會
分析師意見
連貫的機會地圖

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9418

Neurology Drugs Market is estimated to be valued at USD 74 Bn in 2026 and is expected to reach USD 104 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.98% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 74 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.98%	2033 Value Projection:	USD 104 Bn

The global neurology drugs market is an important segment of the pharmaceutical industry, and its scope is to address complex diseases affecting the central and peripheral nervous systems.

Neurology drugs include treatments for various diseases, such as epilepsy, Alzheimer's, Parkinson's, multiple sclerosis, migraine, stroke, and many more. The growth of the neurology drugs market is mainly propelled by an increase in the prevalence of neurological disorders, rising aging population, and an increased understanding of neurobiological mechanisms. The increased prevalence of neurological diseases, particularly in developed and emerging countries, is a key driver of the growth of the neurology drugs market.

On the other hand, there are increased R&D activities by companies to introduce new therapies such as drug delivery systems, personalization of medicine, and new therapies for different conditions. The market is highly regulated, with clinical validation due to a complex risk profile associated with therapies for neurological conditions. Major factors such as patent expiration, generics, changes in healthcare infrastructure, and changes in clinical guidelines are other key drivers for this market. Furthermore, gene therapy, immunotherapy, and precision medicine are changing the current therapy landscape, thus providing new opportunities for the management of this condition.

Market Dynamics

The global neurology drugs market is fueled by various factors related to demography, technology, and healthcare. Growing cases of dementia, Parkinson's disease, and epilepsy among the aging population contribute to the growth of the neurology drugs market. Improvements in drug discovery techniques, including the application of artificial intelligence in drug discovery, the identification of biomarkers, and the application of precision medicine, further propels the growth. Additionally, increasing healthcare expenditure, improvements in diagnostic techniques, and the expansion of the healthcare infrastructure in emerging markets also contribute to the growth of the neurology drugs market.

However, there are certain challenges in this market, which include high R&D costs and regulatory approvals, which act as a restraint in this market for new entrants. The expiration of patents on blockbuster drugs creates a competitive environment in the generics segment, which affects the revenue received by these companies. Challenges in clinical trials, ethical issues, and high failure rates in late-stage drug development are other issues in this market. In addition, there are safety issues and the occurrence of adverse effects, which necessitate surveillance in this market.

Despite the challenges, there are many opportunities in this market, especially in the new markets of developing nations, which are growing in terms of healthcare infrastructure and medical tourism. Orphan drugs for neurological disorders, digital therapeutics, combination therapies, and drug delivery systems are opportunities in this market for future growth.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neurology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Merck & Co., Teva Pharmaceutical Industries, Eisai, H. Lundbeck, UCB, Otsuka Pharmaceutical, and Jazz Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neurology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurology drugs market

Market Segmentation

Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Alzheimer's Disease
- Parkinson's Disease
- Epilepsy
- Multiple Sclerosis
- Migraine
- Huntington's Disease
- Others
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Antiepileptics
- Antipsychotics
- Dopamine Agonists
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Analgesics (Migraine-specific)
- Others
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Injectable
- Transdermal
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- F. Hoffmann-La Roche
- Johnson & Johnson
- AbbVie
- Merck & Co.
- Teva Pharmaceutical Industries
- Eisai
- Lundbeck
- UCB
- Otsuka Pharmaceutical
- Jazz Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Neurology Drugs Market, By Disease Type
- Global Neurology Drugs Market, By Drug Class
- Global Neurology Drugs Market, By Route of Administration
- Global Neurology Drugs Market, By Distribution Channel
- Global Neurology Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Neurology Drugs Market, By Disease Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Alzheimer's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Parkinson's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Migraine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Huntington's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Neurology Drugs Market, By Drug Class, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Antiepileptics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Dopamine Agonists
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
NMDA Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Analgesics (Migraine-specific)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Neurology Drugs Market, By Route of Administration, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Neurology Drugs Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global Neurology Drugs Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eisai
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Jazz Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies